Theratechnologies Inc T.TH

Wow! THTX is way off the radar screen of investors

[SPCEO1]

It is really quite a remarkable thing that is happening with THTX. More than a hour into trading a few days before a webinar that could contain some very important news on their very intriguing cancer drug and only 3,800 shares have traded on NASDAQ? 

I think we can safely say that whatever efforts the company and LSA have made to create some excitement around the webinar on Monday have failed. Either that or the market has been able to somehow figure out there will be nothing of real interst said on Monday. 

The concern is even if they have something important to say on Monday, no one other than us die-hard fans will hear it. And, therefore, it will not get properly reflected int he price of the shares.

THTX seems to be doing the appropriate things to draw attention to the stock and the webinar, but if trading volume is a good indication about investor excitement surrounding a stock, there is none regarding THTX. Which makes so little sense given that the cancer opportunity should be something that generates investor excitement. It excited the FDA enough to give them Fast Track status before trials even started and it excited cancer-investing specialist Soleus enough to make it their second largest holding. It is hard to understand why that excitement seems to end with those two entities.

[scarlet1967]

The point is when you run a business you need to constantly be on or just below that ethical line to promote your business otherwise the costs kills it specifically in the beginning before your reserve funds start drying up. You run the business as your standard of life depends on it. The LSA is the start but ultimately the company needs to keep promoting in a very competitive environment

[qwerty22]

Do webinars generate volume? A genuine question. If it was organized late May/early June then there is a perfect scenario where it's organized based on meaningful data. But how much do you believe in perfect scenarios? I think it's probably best understood as an introduction to the cancer program. It's an invitation to listen rather than a reason to buy.  

[SPCEO1]

That is most likely right - it is an invitation to start paying attention because TH might have something very important to share in a month or three about this intriguing cancer drug platform that could end up being a very significant development in cancer research. But, who knows, we may also get some very strong hints about where things are heading on Monday. That being said, I did notice that